Details of the Drug Formulations

General Information of Drug (ID: DMCOZJY)

• Drug Name: Tenapanor Drug Info
• Synonyms: 1234423-95-0; UNII-WYD79216A6; AZD 1722; WYD79216A6; AZD-1722; 3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(26-((3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl)sulfonamido)-10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosyl)benzenesulfonamide; Tenapanor [USAN:INN]; Tenapanor(free base); GTPL8449; CHEMBL3304485; SCHEMBL15267600; DTXSID40154016; BCP24892; BCP28554; EX-A2506

Indication

Disease Entry	ICD 11	Status	REF
Irritable bowel syndrome	DD91.0	Approved	[1]
Constipation	DD91.1	Phase 2	[2]
Kidney disease	GC2Z	Phase 2	[3]

• Cross-matching ID:
  PubChem CID: 71587953
  CAS Number: 1234423-95-0
  TTD ID: D04TQO
  INTEDE ID: DR1549
  ACDINA ID: D01472

Full List of Drug Formulations Containing This Drug

Tenapanor 50 mg tablet

Company	Formulation ID	FDA Description
Ardelyx	F23304	Colloidal Silicon Dioxide; Hypromellose; Low-Substituted Hydroxypropyl Cellulose; Microcrystalline Cellulose; Propyl Gallate; Stearic Acid; Tartaric Acid Powder; Titanium Dioxide; Triacetin

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] ClinicalTrials.gov (NCT01340053) A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C). U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT01764854) Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis. U.S. National Institutes of Health.